Zur Merkliste hinzufügen


44814-01 - Vorlesung: Target Validation and Identification of Modulators: exemplified by Therapeutics in Immune Pharmacology 1 KP

Semester Herbstsemester 2022
Angebotsmuster Jedes Herbstsemester
Dozierende Christoph Burkhart (christoph.burkhart@unibas.ch)
Thomas Calzascia (thomas.calzascia@unibas.ch)
Tobias Junt (tobias.junt@unibas.ch, BeurteilerIn)
Gisbert Weckbecker (gisbert.weckbecker@unibas.ch)
Lernziele The student will understand
- concepts of basic immunology and key signaling events in immune cells as prerequisites for the discovery of new targets and immunomodulatory drugs
- the medical need in key immunological disorders such as multiple sclerosis, lupus and transplant rejection
- the discovery und use of standard immunosuppressive drugs such as cyclosporine and rapamycins and their limitations as a motivation for further drug discovery
- the discovery of new immunomodulatory drugs with more specific profiles such as interference with cell migration, co-stimulation and nucleic acid sensing (drugs include natalizumab and fingolimod)
- that PI3 kinase inhibitors offer new opportunities to interfere with the activation and function of various immune cells that are involved in immune disorders or cancer (drugs include idelalisib and duvelisib)
- how activators of immune cells are becoming successful new treatment options for cancer and infections (drugs include anti-CTLA-4 Ab, anti-PD-1 and anti-PD-L1 Abs)
- use of immune cell depletion strategies to fight immune disorders, e.g. MS
Literatur Textbooks (in English):

Consider to watch Grand Rounds (e.g. Harvard or Stanford University) on related topics
Immunology. A Short Course. 7th Edition, R. Coico G. Sunshine
Cellular and Molecular Immunology, 8th Edition, A. Abbas, A. Lichtman, S. Pillai
Janeway's Immunobiology 9th edition (2016)


Lectures 1 and 2
Waring M et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat Rev Drug Disc, online, 1.

Haijuan Y et al (2013) mTOR kinase structure, mechanism and regulation Nature 497, 217.

Gurk-Turner,C et al (2012) A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor Transplantation 94, 659.

McInnes IB (2011) The Pathogenesis of Rheumatoid Arthritis N Engl J Med 365, 2205.

Case, JP (2001) Old and New Drugs Used in Rheumatoid Arthritis: A Historical Perspective. Part 1: The Older Drugs Am J Therapeutics 8, 123.

Koné-Paut, et al (2012) Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes. What did we learn? Autoimmunity Reviews 12, 77.

Lectures 3 and 4
Junt T, Barchet W (2015) Translating nucleic acid-sensing pathways into therapies Nat Rev Immunol 15, 529

Kinnear G et al (2013) Co-stimulation blockade: current perspectives and implications for therapy Transplantation 95, 527.

Ley K et al (2016) Integrin-based therapeutics: biological basis, clinical use and new drugs Nat Rev Drug Discov 15 (3), 173.

Chun J, Brinkmann VA (2011) Mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discov Med 12(64), 213.

Lecture 5
Vanhaesebroeck B et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329.

Stark AK et al (2015) PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol 23, 82.

Lucas C et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15, 88.

Lecture 6
Robert C et al (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation N Engl J Med 372, 320.

Egen JG et al (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy Nature Immunol 3, 611.

Lecture 6
Larkin J et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma , N Engl J Med 373, 23.

Khalil DN et al (2016) The future of cancer treatment: immunomodulation, CARs and combination therapy, Nat Rev Clin Onc 13, 273.

Bemerkungen Researchers in Basel have contributed very significantly to the fields of immuno-pharmacology and inflammation (e.g. cyclosporine, everolimus, ofatumumab, ocrelizumab, fingolimod, PI3 kinase inhibitors, diclofenac).

Film and sound recordings during the course are strictly forbidden (recorders may be confiscated)
Weblink Department of Pharmaceutical Sciences


Teilnahmebedingungen Completed Bachelor degree
Unterrichtssprache Englisch
Einsatz digitaler Medien kein spezifischer Einsatz


Intervall wöchentlich
Datum 21.09.2022 – 26.10.2022
Zeit Mittwoch, 10.15-12.00 Biozentrum, Seminarraum U1.191
Datum Zeit Raum
Mittwoch 21.09.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 28.09.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 05.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 12.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 19.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 26.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Module Modul: Target Identification/Validation to Discovery of Modulators (Masterstudium: Drug Sciences)
Modul: Vertiefung Medizinische Nanowissenschaften (Masterstudium: Nanowissenschaften)
Wahlbereich Master Pharmazie: Empfehlungen (Masterstudium: Pharmazie)
Leistungsüberprüfung Lehrveranst.-begleitend
Hinweise zur Leistungsüberprüfung refer to this link: https://pharma.unibas.ch/en/education/assessments-and-credit-points/continuous-assessments/
An-/Abmeldung zur Leistungsüberprüfung An-/Abmelden: Belegen resp. Stornieren der Belegung via MOnA
Wiederholungsprüfung keine Wiederholungsprüfung
Skala 1-6 0,5
Wiederholtes Belegen beliebig wiederholbar
Zuständige Fakultät Philosophisch-Naturwissenschaftliche Fakultät, studiendekanat-philnat@unibas.ch
Anbietende Organisationseinheit Departement Pharmazeutische Wissenschaften